Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$8.25 USD
-0.10 (-1.20%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $8.25 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANIK 8.25 -0.10(-1.20%)
Will ANIK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANIK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIK
Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
ANIK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion Pharmaceuticals (RXRX) Soars 5.8%: Is Further Upside Left in the Stock?
Company News for May 12, 2025
Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
Other News for ANIK
Anika Therapeutics (ANIK) Target Price Reduced Amidst Market Skepticism
Anika Therapeutics (ANIK): Analyst Updates Price Target | ANIK Stock News
Anika Therapeutics price target lowered by $4 at Barrington, here's why
Anika Therapeutics Inc (ANIK) Q2 2025 Earnings Call Highlights: Navigating Challenges with ...
12 Health Care Stocks Moving In Wednesday's Intraday Session